Biofrontera Achieves Significant Milestone in Phase 3 Study
Biofrontera Inc. has reached an important milestone in their Phase 3 study focused on Ameluz®-photodynamic therapy (PDT) for treating superficial basal cell carcinoma (sBCC). The company's last patient completed the one-year follow-up, signifying a major step toward advancing their clinical program. This achievement, which follows rigorous evaluation, has set the stage for FDA submission, expected in the near future.
Details of the Phase 3 Study
The Phase 3 study, designated ALA-BCC-CT013, undertook a randomized, double-blind, and placebo-controlled approach involving 187 patients with confirmed sBCC diagnoses. Participants underwent PDT treatments, alternating between either Ameluz® or placebo at an interval of one to two weeks. Any lesions that remained unresolved after a three-month period were subjected to additional treatment cycles. This structured follow-up is critical as the FDA has emphasized the importance of these extensive evaluations in dermatologic treatments, especially for skin cancers.
Highlights of Study Results
In October, Biofrontera shared results showcasing a highly statistically significant outcome for both primary and secondary endpoints, indicating the therapeutic potential of Ameluz® in this area. In particular, the data collected during the study showed promising efficacy against sBCC, emphasizing the importance of long-term monitoring for patients diagnosed with these lesions.
Long-term Follow-up and Future Steps
Following the one-year data collection, patients will continue to be monitored for a total of five years, providing a comprehensive view of treatment outcomes. The prolonged follow-up is essential, given the potential for local recurrence of sBCC or subsequent skin cancer events. Dr. Hermann Luebbert, CEO and Chairman of Biofrontera, expressed his enthusiasm about the results so far and highlighted the commitment of the company to enhancing care for patients through innovative treatment options.
Expert Opinions on Ameluz® Treatment
Dr. Shane Chapman, a dermatologist involved in the study, remarked on the efficacy of PDT in treating actinic keratoses and expressed optimism about incorporating Ameluz-PDT as a treatment alternative for patients with sBCC. Insights from professionals reinforce the significance of Biofrontera’s work in advancing treatment methodologies in the field of dermatology.
Understanding Basal Cell Carcinoma
Basal cell carcinoma (BCC) represents the most prevalent skin cancer type, with millions of new cases diagnosed annually. sBCC, a common subclass, develops from the abnormal growth of basal cells in the skin's lowest layer. While BCCs rarely metastasize, they could pose serious local health risks if not treated effectively, reiterating the necessity for options like Ameluz® to address this concern.
About Biofrontera Inc.
Headquartered in the U.S., Biofrontera Inc. is dedicated to the advancement of dermatological therapies, especially through the use of PDT. The company's flagship product, Ameluz®, is paired with the RhodoLED® lamp series to tackle various skin lesions and offer preventive measures against more severe skin malignancies. Biofrontera remains focused on expanding its research to include additional dermatological conditions, helping improve patient outcomes through advanced clinical trials.
Frequently Asked Questions
What milestone did Biofrontera achieve in their recent study?
Biofrontera completed a one-year follow-up of their Phase 3 study for Ameluz® in treating superficial basal cell carcinoma (sBCC).
What is Ameluz® used for?
Ameluz® is a photodynamic therapy treatment aimed at treating superficial basal cell carcinoma and actinic keratoses, used to prevent more serious skin lesions.
How many patients were involved in the Phase 3 study?
The Phase 3 study involved 187 patients who were closely monitored to track the treatment efficacy and safety of Ameluz®.
What did the recent study results indicate?
The study results indicated highly statistically significant outcomes for both primary and secondary endpoints, showcasing Ameluz's effectiveness against sBCC.
What is the plan following the completion of the one-year follow-up?
After the one-year data collection, patients will be monitored for an additional four years to assess long-term treatment outcomes and safety.
